ENA 2022 Poster 321

High Content Screening of Ovarian Organoid Models to Accelerate Anti-Cancer Drug Discovery

Marten Hornsveld, Mariusz Madej, Esther Kingma, Jara García Mateos, Xiaoxi Xu, Saskia de Man, Gera Goverse, Marrit Putker, Emma Spanjaard, Leo Price, and Bram Herpers

In this study, a pipeline that combines high content imaging (HCI) phenotype-based and in vivo analysis of 3D cultured ovarian tumor organoid models is presented. This platform allows the measurement of pre-clinical relevant endpoints beyond conventional cell viability, including those associated with tumor killing, growth inhibition, toxicity, different types of cell death and interactions with imm.

Download this Poster to Discover:

• The feasibility of in-depth, rapid, reproducible and physiologically relevant screening a wide variety of chemo, targeted and immune therapies in ovarian cancer.
  
  
• How an ovarian organoid screening platform can represent a significant advance in pre-clinical screening compared to conventional in vitro models.
  
  
• How to facilitate rapid drug implementation in clinical trails and cost-waste reduction by reliable prediction of drug effects early in the drug development pipeline.

Download the Poster Now!